Asset Details
Do you wish to reserve the book?
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia
Do you wish to request the book?
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia
2024
Overview
Chronic myeloid leukemia (CML) is a malignant clonal disease involving hematopoietic stem cells that is characterized by myeloid cell proliferation in bone marrow and peripheral blood, and the presence of the Philadelphia (Ph) chromosome with BCR-ABL fusion gene. Treatment of CML has dramatically improved since the advent of tyrosine kinase inhibitors (TKI). However, there are a small subset of CML patients who develop resistance to TKI. Mutations in the ABL kinase domain (KD) are currently recognized as the leading cause of TKI resistance in CML. In this review, we discuss the concept of resistance and summarize recent advances exploring the mechanisms underlying CML resistance. Overcoming TKI resistance appears to be the most successful approach to reduce the burden of leukemia and enhance cures for CML. Advances in new strategies to combat drug resistance may rapidly change the management of TKI-resistant CML and expand the prospects for available therapies.
Publisher
Ivyspring International Publisher Pty Ltd,Ivyspring International Publisher
Subject
/ Drug Resistance, Neoplasm - genetics
/ Fusion Proteins, bcr-abl - genetics
/ Fusion Proteins, bcr-abl - therapeutic use
/ Humans
/ Kinases
/ Leukemia
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology
/ Mutation
/ Protein Kinase Inhibitors - pharmacology
/ Protein Kinase Inhibitors - therapeutic use
/ Proteins
/ Review
/ Tyrosine
